Anastrozole
Arimidex (anastrozole) is a small molecule pharmaceutical. Anastrozole was first approved as Arimidex on 1995-12-27. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against aromatase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Arimidex (generic drugs available since 2010-06-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Anastrozole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARIMIDEX | ANI Pharmaceuticals | N-020541 RX | 1995-12-27 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| anastrozole | ANDA | 2023-04-24 |
| arimidex | New Drug Application | 2019-10-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0170 | Anastrozole, oral, 1 mg |
Clinical
Clinical Trials
275 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 16 | 93 | 57 | 10 | 28 | 198 |
| Male breast neoplasms | D018567 | — | 5 | 2 | 1 | 2 | 10 | ||
| Hypogonadism | D007006 | E23.0 | 1 | 3 | — | 2 | 1 | 7 | |
| Invasive hydatidiform mole | D002820 | D39.2 | 2 | 1 | 2 | 1 | — | 6 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | 2 | 3 | 6 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 1 | — | 2 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | 8 | 4 | — | — | 12 | ||
| Neoplasms | D009369 | C80 | 5 | 3 | 1 | — | — | 8 | |
| Ductal carcinoma breast | D018270 | — | — | 2 | — | — | 2 | ||
| Gynecomastia | D006177 | HP_0000771 | N62 | — | 1 | 1 | — | — | 2 |
| Progression-free survival | D000077982 | — | — | 1 | — | — | 1 | ||
| Bone density | D015519 | EFO_0003923 | M85 | — | — | 1 | — | — | 1 |
| Oligospermia | D009845 | N46.1 | — | — | 1 | — | — | 1 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | 1 | 1 | — | — | 1 |
| Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 8 | 1 | — | — | 1 | 10 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 2 | 4 | — | — | — | 5 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | — | — | — | 4 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | 1 | — | — | 1 | 3 |
| Non-small-cell lung carcinoma | D002289 | 1 | 1 | — | — | — | 2 | ||
| Pulmonary arterial hypertension | D000081029 | — | 2 | — | — | — | 2 | ||
| Intraductal carcinoma noninfiltrating | D002285 | D05.1 | — | 2 | — | — | — | 2 | |
| Eunuchism | D005058 | EFO_0007266 | E29.1 | — | 1 | — | — | — | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | 1 | 2 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | 1 | — | — | — | — | 1 |
| Breast density | D000071060 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | — | — | 5 | 5 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | — | — | 1 | 1 |
| Silver-russell syndrome | D056730 | Orphanet_813 | Q87.19 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | 1 | 1 | |
| Musculoskeletal pain | D059352 | — | — | — | — | 1 | 1 | ||
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ANASTROZOLE |
| INN | anastrozole |
| Description | Anastrozole is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile. |
| Classification | Small molecule |
| Drug class | aromatase inhibitors (imidazole/triazole derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1 |
Identifiers
| PDB | — |
| CAS-ID | 120511-73-1 |
| RxCUI | 84857 |
| ChEMBL ID | CHEMBL1399 |
| ChEBI ID | 2704 |
| PubChem CID | 2187 |
| DrugBank | DB01217 |
| UNII ID | 2Z07MYW1AZ (ChemIDplus, GSRS) |
Target
Agency Approved
CYP19A1
CYP19A1
Organism
Homo sapiens
Gene name
CYP19A1
Gene synonyms
ARO1, CYAR, CYP19
NCBI Gene ID
Protein name
aromatase
Protein synonyms
CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, cytochrome P450, family 19, subfamily A, polypeptide 1, cytochrome P450, subfamily XIX (aromatization of androgens), Estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Uniprot ID
Mouse ortholog
Cyp19a1 (13075)
aromatase (P28649)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Arimidex - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,688 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,384 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more